

[Curr Opin Mol Ther](#). 2003 Apr;5(2):204-7.

Technology evaluation: TriGem, Titan.

[Razis E](#), [Fountzilas G](#).

Source

First Department of Internal Medicine, Aristotle University of Thessaloniki Medical School, Thessaloniki, Macedonia, Greece.

Abstract

Titan (formerly Trilex) is developing TriGem, a monoclonal antibody directed against I17, for the potential treatment of advanced cancers that express the GD2 ganglioside, including melanoma, small-cell lung cancer, neuroblastoma and sarcoma. Phase II trials of TriGem for use in advanced melanoma were ongoing by June 2002. TriGem also has potential for the treatment of psoriasis, for which phase II trials had begun by 1996.